A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy

Tian, Hailong; Zhao, Sai; Nice, Edouard C.; Huang, Canhua; Wang, He; Zou, Bingwen; Lin, Jie

doi:10.1016/j.jcis.2021.09.049

Cited by 53 publications

(37 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemodynamic therapy (CDT) based on the Fenton reaction, which catalyses hydrogen dioxide (H 2 O 2 ) into highly toxic hydroxyl radicals (∙OH) by iron ions, has emerged as a novel therapeutic approach for cancer through oxidative damage of lipids, proteins and DNA [ 8 ]. Recently, copper-based Fenton-like reactions with higher reaction rates in a broader pH range showed more possibilities for highly efficient CDT [ 9 – 13 ]. However, copper is a trace element in the body incapable of inducing sufficient therapeutic efficacy alone, which would induce toxicity to normal cells at high concentrations [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Tumor microenvironment-responsive BSA nanocarriers for combined chemo/chemodynamic cancer therapy

Zhang

Teng

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Tumor microenvironment (TME), characterized by high glutathione (GSH), high hydrogen peroxide (H2O2) and acidic pH levels, is favorable for the growth, invasion and metastasis of cancer cells. Taking advantage of the specific characteristics of tumors, TME-responsive GCBD NPs are designed to deliver nanoscale coordination polymers (NCPs, GA-Cu) and chemotherapy drugs (doxorubicin, DOX) based on bovine serum albumin (BSA) nanocarriers into cancer cells for combined chemodynamic therapy (CDT) and chemotherapy. In an acidic environment, GCBD NPs could release approximately 90% copper ions, which can not only consume overexpressed GSH to modulate the TME but can also react with endogenous H2O2 in a Fenton-like reaction to achieve the CDT effect. Meanwhile, the released DOX could enter the nucleus of tumor cells and affect their proliferation to achieve efficient chemotherapy. Both in vitro and in vivo experiments showed that GCBD NPs had good biosafety and could effectively inhibit the growth of cancer cells. GCBD NPs are promising as a biocompatible nanoplatform to exploit TME characteristics for combined chemo and chemodynamic therapy, providing a novel strategy to eradicate tumors with high efficiency and specificity. Graphical Abstract

show abstract

Section: Introductionmentioning

confidence: 99%

Tumor microenvironment-responsive BSA nanocarriers for combined chemo/chemodynamic cancer therapy

Zhang

Teng

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Another nanoparticle-based approach used a cascaded copper-based metallo–organic framework nanocatalyst which bears the cyclooxygenase-2 inhibitor meloxicam and the targeted agent sorafenib to amplify the efficiency of HCC therapy by ferroptosis [ 123 ].…”

Section: The Translation Of Ferroptosis Into Clinical Hcc Practicementioning

confidence: 99%

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation

Bekric

Ocker

Mayr

et al. 2022

Cancers

View full text Add to dashboard Cite

Ferroptosis, an iron and reactive oxygen species (ROS)-dependent non-apoptotic type of regulated cell death, is characterized by a massive iron overload and peroxidation of polyunsaturated fatty acids (PUFAs), which finally results in cell death. Recent studies suggest that ferroptosis can influence carcinogenesis negatively and therefore may be used as a novel anti-cancer strategy. Hepatocellular carcinoma (HCC) is a deadly malignancy with poor chances of survival and is the second leading cause of cancer deaths worldwide. Diagnosis at an already late stage and general resistance to current therapies may be responsible for the dismal outcome. As the liver acts as a key factor in iron metabolism, ferroptosis is shown to play an important role in HCC carcinogenesis and, more importantly, may hold the potential to eradicate HCC. In this review, we summarize the current knowledge we have of the role of ferroptosis in HCC and the application of ferroptosis as a therapy option and provide an overview of the potential translation of ferroptosis in the clinical practice of HCC.

show abstract

“…However, DSF/Cu also compensatively activated p62-Keap1-Nrf2 antioxidant pathway, which in turn showed a protective effect in ferroptosis [ 36 , 37 ]. In addition, various copper complexes [ 38 ] and copper complex nanoformulations [ 39 , 40 ] have been demonstrated to induce ferroptosis.…”

Section: Copper Metabolismmentioning

confidence: 99%

Research Progress of Ferroptosis in Adiposity-Based Chronic Disease (ABCD)

Ren

Bai

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Ferroptosis is a multistep regulated cell death process induced by iron accumulation and lipid peroxidation. Classical GPX4-dependent pathway and GPX4-independent pathways can independently and synergistically inhibit ferroptosis and jointly maintain the oxidative balance of the body. WHO defines obesity as “a condition of abnormal or excessive fat accumulation in adipose tissue, to the extent that health may be impaired,” and obesity is also defined as an adiposity-based chronic disease (ABCD). Obesity is a systemic disease that leads to metabolic abnormalities in various systems, resulting in a series of complications including obesity cardiomyopathy, atherosclerosis, nonalcoholic fatty liver disease, and diabetes mellitus. Emerging evidence shows that ferroptosis is closely associated with the occurrence and progression of various diseases. In recent years, ferroptosis has been found to play critical roles in obesity and its complications. This review discusses the mechanisms of how ferroptosis is initiated and controlled and discusses the research progress of ferroptosis in obesity and its complications.

show abstract

A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy

Cited by 53 publications

References 46 publications

Tumor microenvironment-responsive BSA nanocarriers for combined chemo/chemodynamic cancer therapy

Tumor microenvironment-responsive BSA nanocarriers for combined chemo/chemodynamic cancer therapy

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation

Research Progress of Ferroptosis in Adiposity-Based Chronic Disease (ABCD)

Contact Info

Product

Resources

About